[{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Foundation Medicine | Myriad genetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"pharma& \/ Foundation Medicine | Myriad genetics","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Foundation Medicine | Myriad genetics"},{"orgOrder":0,"company":"pharma&","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"pharma& \/ Foundation Medicine","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Foundation Medicine"},{"orgOrder":0,"company":"pharma&","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"pharma& \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"pharma& \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"pharma& \/ Foundation Medicine","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Foundation Medicine"},{"orgOrder":0,"company":"pharma&","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"pharma& \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"pharma& \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Foundation Medicine","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Foundation Medicine"},{"orgOrder":0,"company":"pharma&","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Bristol Myers Squibb | GOG Foundation | European Network for Gynaecological Oncological Trial Groups | Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Bristol Myers Squibb | GOG Foundation | European Network for Gynaecological Oncological Trial Groups | Foundation Medicine","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Bristol Myers Squibb | GOG Foundation | European Network for Gynaecological Oncological Trial Groups | Foundation Medicine"},{"orgOrder":0,"company":"pharma&","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Foundation Medicine","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Foundation Medicine"},{"orgOrder":0,"company":"pharma&","sponsor":"Foundation Medicine | Myriad genetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Foundation Medicine | Myriad genetics","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Foundation Medicine | Myriad genetics"},{"orgOrder":0,"company":"pharma&","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"pharma& \/ Foundation Medicine"},{"orgOrder":0,"company":"pharma&","sponsor":"Bristol Myers Squibb | Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Bristol Myers Squibb | Foundation Medicine","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Bristol Myers Squibb | Foundation Medicine"},{"orgOrder":0,"company":"pharma&","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"pharma& \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"pharma& \/ Gilead Sciences"},{"orgOrder":0,"company":"pharma&","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"pharma& \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"pharma& \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"pharma& \/ Undisclosed"},{"orgOrder":0,"company":"pharma&","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"pharma& \/ Tolmar"},{"orgOrder":0,"company":"NSGO-CTU","sponsor":"Institute of Cancer Research, United Kingdom | Central and Eastern European Oncology Group | North Eastern German Society of Gynaecological Oncology | Belgian Gynaecological Oncology Group | Princess Margaret Hospital | Polish Gynaecologic Oncology Group ","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"NSGO-CTU","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NSGO-CTU \/ Institute of Cancer Research, United Kingdom | Central and Eastern European Oncology Group | North Eastern German Society of Gynaecological Oncology | Belgian Gynaecological Oncology Group | Princess Margaret Hospital | Polish Gynaecologic Oncology Group ","highestDevelopmentStatusID":"8","companyTruncated":"NSGO-CTU \/ Institute of Cancer Research, United Kingdom | Central and Eastern European Oncology Group | North Eastern German Society of Gynaecological Oncology | Belgian Gynaecological Oncology Group | Princess Margaret Hospital | Polish Gynaecologic Oncology Group "},{"orgOrder":0,"company":"UNICANCER","sponsor":"Clovis Oncology | Fondation ARC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNICANCER \/ Clovis Oncology | Fondation ARC","highestDevelopmentStatusID":"8","companyTruncated":"UNICANCER \/ Clovis Oncology | Fondation ARC"},{"orgOrder":0,"company":"University of Leicester","sponsor":"British Lung Foundation | Clovis Oncology | Eli Lilly | Merck & Co | BerGenBio ASA | F. Hoffmann-La Roche | University Hospitals of Leicester | The Christie NHS Foundation Trust | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"University of Leicester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leicester \/ British Lung Foundation | Clovis Oncology | Eli Lilly | Merck & Co | BerGenBio ASA | F. Hoffmann-La Roche | University Hospitals of Leicester | The Christie NHS Foundation Trust | GSK","highestDevelopmentStatusID":"8","companyTruncated":"University of Leicester \/ British Lung Foundation | Clovis Oncology | Eli Lilly | Merck & Co | BerGenBio ASA | F. Hoffmann-La Roche | University Hospitals of Leicester | The Christie NHS Foundation Trust | GSK"},{"orgOrder":0,"company":"North Eastern German Society of Gynaecological Oncology","sponsor":"IKF Nordwest | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"North Eastern German Society of Gynaecological Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North Eastern German Society of Gynaecological Oncology \/ IKF Nordwest | Clovis Oncology","highestDevelopmentStatusID":"10","companyTruncated":"North Eastern German Society of Gynaecological Oncology \/ IKF Nordwest | Clovis Oncology"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Clovis Oncology | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Clovis Oncology | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ Clovis Oncology | National Cancer Institute"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Bristol Myers Squibb | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Bristol Myers Squibb | Clovis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Chicago \/ Bristol Myers Squibb | Clovis Oncology"},{"orgOrder":0,"company":"University of Kansas Medical Center","sponsor":"Bristol Myers Squibb | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Kansas Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Kansas Medical Center \/ Bristol Myers Squibb | Clovis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Kansas Medical Center \/ Bristol Myers Squibb | Clovis Oncology"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Clovis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Clovis Oncology"},{"orgOrder":0,"company":"University of Oklahoma","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"University of Oklahoma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oklahoma \/ Clovis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"University of Oklahoma \/ Clovis Oncology"},{"orgOrder":0,"company":"Brown University","sponsor":"Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Brown University \/ Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology"},{"orgOrder":0,"company":"University of Utah","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Clovis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"University of Utah \/ Clovis Oncology"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Genentech | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical College of Wisconsin \/ Genentech | Clovis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Medical College of Wisconsin \/ Genentech | Clovis Oncology"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Bristol Myers Squibb | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb | Clovis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb | Clovis Oncology"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Clovis Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Clovis Oncology"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDR Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"US Oncology Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"US Oncology Network","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US Oncology Network \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"US Oncology Network \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ J.P. Morgan"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Zhonglin Hao","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Zhonglin Hao","highestDevelopmentStatusID":"8","companyTruncated":"Clovis Oncology \/ Zhonglin Hao"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Pamela Munster","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Pamela Munster","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Oncology \/ Pamela Munster"},{"orgOrder":0,"company":"Tolmar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1 | PARP 2 | PARP 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tolmar \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Rucaparib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
